NCT02607813

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 142 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.

Conditions

• NSCLC
• Ovarian Cancer
• Melanoma
• Other Solid Tumors

Interventions

Type	Name	Description
DRUG	LXH254	pan-RAF inhibitor
DRUG	PDR001	Biological: PDR001 anti-PD1 antibody

Timeline

• Start date: 2016-01-18
• Primary completion: 2022-02-18
• Completion: 2022-02-19
• First posted: 2015-11-18
• Last updated: 2022-12-21

Locations

18 sites across 10 countries: United States, Canada, France, Germany, Italy, Japan, Netherlands, South Korea, Spain, Switzerland

Regulatory

• FDA-regulated drug study